Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

Part of paid clinical trials in DeKalb, Illinois.

Sponsor
Northwestern University
Study ID
NCT04616131
Status
Recruiting
Apply to this trial

Conditions

  • Pancreas Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Key Dates

Start date
Oct 1, 2020
Status verified
Jun 2026
Primary completion
Oct 1, 2027
Completion
Oct 1, 2029

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected. [ Time Frame: 3 months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Northwestern Medicine Cancer Center KishwaukeeDeKalbIllinois60115
Donald Smith
[email protected]
630-352-5360
Northwestern Medicine Cancer Center DelnorGenevaIllinois60135
Donald Smith
[email protected]
630-352-5360
Northwestern Medicine Cancer Center WarrenvilleWarrenvilleIllinois60555
Akhil Chawla, MD
[email protected]
630-352-5353

Find similar trials in DeKalb, IL

By research site
Northwestern Medicine Cancer Center Kishwaukee· DeKalb, ILNorthwestern Medicine Cancer Center Delnor· Geneva, ILNorthwestern Medicine Cancer Center Warrenville· Warrenville, IL

Related Studies